A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

NCT04661150 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Atezolizumab
DRUG: Trastuzumab
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Hoffmann-La Roche